#United States #Boston #CereVasc #eShunt System #Tony Kingsley

Tony Kingsley Takes the Helm at CereVasc, Inc.

CereVasc, Inc., a promising clinical-stage medical device company, has just announced a pivotal change within its leadership team. Effective September 15, 2026, Tony Kingsley will step into the role of President and Chief Executive Officer (CEO). He will succeed Dan Levangie, who played a crucial part in the growth and direction of the company, moving into the role of Chairman of the Board. This transition marks a significant moment for CereVasc as it gears up for the commercial launch of its groundbreaking eShunt System.

Tony Kingsley brings a wealth of leadership experience, particularly in the healthcare sector, which is increasingly essential as CereVasc prepares for the introduction of its innovative medical device. Previously, Kingsley has demonstrated a robust ability to lead companies toward success in the neurological field, making him an excellent fit for this leadership role.

In his statement regarding the appointment, Dan Levangie expressed his enthusiasm for Kingsley’s arrival, stating, “We are thrilled to welcome Tony to CereVasc. His extensive experience in commercial leadership, especially in neurology, along with his passion for meaningful healthcare solutions, makes him a perfect choice to lead the company into its future.”

Levangie has been instrumental in positioning CereVasc as a leader in interventional neurosurgery, guiding the company's transformation from a concept stage to a viable alternative for treating conditions like communicating hydrocephalus. Under his leadership, over 200 patients have successfully undergone treatment with CereVasc's pioneering approaches.

With a mission centered around improving patient care, Kingsley takes the reins at a strategic time. “I am honored and excited to join CereVasc at such an important moment in the company's journey,” Kingsley stated. He acknowledges the firm’s commitment to innovation as a crucial part of their vision and expresses eagerness to build upon the strong foundation that Dan has cultivated.

As Kingsley steps into this key position, he aims to unlock the full potential of CereVasc while fostering collaboration among employees, the Board, and external partners. His proactive strategy is anticipated to not only enhance operational flow but to also spearhead advanced solutions aimed at alleviating the challenges faced by patients with neurological disorders.

CereVasc, Inc., nestled in Massachusetts's healthcare hub, focuses on developing novel, minimally invasive treatments specifically for neurological diseases. The company's flagship product, the eShunt System, is specially designed to provide an innovative percutaneous approach to treating conditions such as communicating hydrocephalus. By employing state-of-the-art techniques, the eShunt System aims to offer an alternative that spares patients from the invasiveness of traditional surgery, a hallmark of CereVasc's commitment to patient-centric innovation.

In summary, the appointment of Tony Kingsley as the new CEO of CereVasc, alongside Dan Levangie's continued involvement as Chairman, positions the company strongly for its next chapter. Both leaders are determined to leverage their insights and experiences to navigate the complexities of the healthcare landscape, ensuring that CereVasc retains its trajectory of innovation and growth. As the organization prepares for the eShunt System’s introduction, it embarks on what promises to be an exciting and transformative journey for the future of patient care in neurology.

For further details about CereVasc and its products, interested readers can visit www.cerevasc.com.